Dr Alan Kennedy is the founder of Pulse AI Ltd, a medical technology company based in Belfast. PulseAI has developed PACE, a cloud-based electrocardiogram (ECG) analysis platform that uses machine-learning algorithms to improve the speed and accuracy of cardiac diagnosis. The platform can automatically analyse large amounts of ECG data, provide detailed diagnoses, and is the first of its kind to integrate clinical and consumer ECG data.
To date, Apple has sold over 150 million smartwatches that have an ECG sensor, part of a rapidly growing number of wearable devices that can measure cardiac activity. PulseAI can combine and scale the deployment of this consumer digital information with its growing proprietary database of over one million patients. Together, these help provide a more complete picture of a patient's cardiac health for physicians.
By automating the interpretation of ECG recordings, PulseAI speeds up a process that is usually done manually. If a patient wears a heart monitor for 10 days, they will generate hundreds of thousands of waveforms for a clinician to study. The PACE platform can process and spot over a hundred different cardiac abnormalities, saving time and money by improving the speed and accuracy of ECG interpretation.
Alan says that “the Regional Talent Engines programme has been useful for us as it has provided access to funding as well as training and mentoring. This will help establish and grow our business as we prepare to present our AI ECG platform for government approval in the US”.
PulseAI is working to gain FDA approval in the coming months. The company then plans to raise capital to enable it to enter the US market. Alan feels that his innovation will improve the accuracy, efficiency and accessibility of cardiac diagnosis worldwide and that the US is the best place to demonstrate its potential.
Associated Programme
